Intranasal GHRP-2 Effectively Stimulates Growth Hormone in Short-Stature Children

Intranasal GHRP-2 effectively stimulated GH release in children with short stature, offering a needle-free alternative to injectable GH therapy.

Pihoker, C et al.·The Journal of endocrinology·1997·Moderate Evidenceclinical-trial
RPEP-00422Clinical TrialModerate Evidence1997RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Intranasal GHRP-2 effectively stimulated GH release in children with short stature, demonstrating viability of a needle-free delivery route.

Key Numbers

How They Did This

Clinical trial administering intranasal GHRP-2 to children with short stature and measuring GH responses.

Why This Research Matters

For children who need GH therapy, a nasal spray could eliminate the need for daily injections — a major quality-of-life improvement for pediatric patients.

The Bigger Picture

Intranasal peptide delivery represents a major advance in pediatric endocrinology, potentially replacing painful daily injections with a simple nasal spray.

What This Study Doesn't Tell Us

Clinical trial; specific treatment outcomes, dosing, duration, and sample size not detailed in abstract. Long-term growth effects not assessed.

Questions This Raises

  • ?Does intranasal GHRP-2 produce sufficient GH stimulation for long-term growth improvement?
  • ?How does intranasal bioavailability compare to subcutaneous injection?

Trust & Context

Key Stat:
Needle-free GH stimulation Intranasal GHRP-2 effectively stimulated GH release in children, offering an alternative to daily injections
Evidence Grade:
Moderate clinical evidence from a pediatric trial. Demonstrates intranasal efficacy but long-term treatment effects not assessed.
Study Age:
Published in 1997, this study explored intranasal GHRP delivery that has since informed peptide nasal spray development.
Original Title:
Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.
Published In:
The Journal of endocrinology, 155(1), 79-86 (1997)
Database ID:
RPEP-00422

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can GHRP-2 be taken as a nasal spray?

Yes. This study showed intranasal GHRP-2 effectively stimulates GH release in children. The nasal mucosa allows peptide absorption into the bloodstream without injection.

Why is this important for children?

Children with GH deficiency typically need daily injections, which are painful and stressful. A nasal spray that achieves the same GH stimulation could dramatically improve treatment compliance and quality of life.

Read More on RethinkPeptides

Cite This Study

RPEP-00422·https://rethinkpeptides.com/research/RPEP-00422

APA

Pihoker, C; Badger, T M; Reynolds, G A; Bowers, C Y. (1997). Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.. The Journal of endocrinology, 155(1), 79-86.

MLA

Pihoker, C, et al. "Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.." The Journal of endocrinology, 1997.

RethinkPeptides

RethinkPeptides Research Database. "Treatment effects of intranasal growth hormone releasing pep..." RPEP-00422. Retrieved from https://rethinkpeptides.com/research/pihoker-1997-treatment-effects-of-intranasal

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.